Santhera Pharmaceuticals Holding AG (LON:0QN1)
16.25
+1.91 (13.29%)
Feb 12, 2026, 4:03 PM GMT
LON:0QN1 Revenue
Santhera Pharmaceuticals Holding AG had revenue of 24.01M CHF in the half year ending June 30, 2025, with 509.62% growth. This brings the company's revenue in the last twelve months to 49.02M, down -56.85% year-over-year. In the year 2024, Santhera Pharmaceuticals Holding AG had annual revenue of 39.12M, down -62.17%.
Revenue (ttm)
49.02M CHF
Revenue Growth
-56.85%
P/S Ratio
4.38
Revenue / Employee
624.41K CHF
Employees
79
Market Cap
197.16M GBP
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 39.12M | -64.30M | -62.17% |
| Dec 31, 2023 | 103.41M | 95.94M | 1,283.84% |
| Dec 31, 2022 | 7.47M | 9.07M | - |
| Dec 31, 2021 | -1.60M | -16.60M | - |
| Dec 31, 2020 | 15.01M | -60.37M | -80.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Integrated Diagnostics Holdings | 114.96M |
| Optima Health | 113.75M |
| Animalcare Group | 81.07M |
| Tristel | 46.46M |
Santhera Pharmaceuticals Holding AG News
- 4 weeks ago - Swissmedic Approves Santhera's AGAMREE For Duchenne Muscular Dystrophy - Nasdaq
- 3 months ago - Half Year 2025 Santhera Pharmaceuticals Holding AG Analyst Briefing Transcript - GuruFocus
- 4 months ago - Santhera Partners With Biomedica To Distribute Agamree In Russia - Nasdaq
- 4 months ago - Health Canada Approves Santhera's AGAMREE For Duchenne Muscular Dystrophy - Nasdaq
- 4 months ago - Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Santhera Pharmaceuticals Holding AG 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 5 months ago - Santhera Pharma Stock Down On Wider H1 Loss; Is AGAMREE On Track? - Nasdaq
- 5 months ago - Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India - GlobeNewsWire